An international clinical trial led by University College London demonstrated that combining niraparib, a PARP inhibitor, with standard hormone therapies (abiraterone acetate and prednisone) significantly delays progression in advanced prostate cancer. This therapeutic approach targets aggressive forms of the disease by exploiting DNA repair weaknesses in cancer cells, potentially improving survival outcomes. The findings offer a promising treatment strategy for men with resistant prostate cancer variants.